Ipilimumab, an inhibitor of CTLA-4 on T-cells, was the first drug to improve overall survival in patients with advanced melanoma. Subsequently, inhibitors of PD-1, including nivolumab and pembrolizumab, were shown to be superior to ipilimumab with a more favourable safety profile. The combination of ipilimumab and nivolumab is associated with a further improvement in response rate and progression free survival, however the combination is associated with an increased rate of immune related toxicities. In 2015 the FDA approved the combination for the treatment of BRAF wildtype advanced melanoma. This review will examine the preclinical rational for the combination of ipilimumab and nivolumab as well as the efficacy and toxicity data from clinical trials in patients with advanced melanoma.
Introduction
In the last 5 years the one year overall survival (OS) of patients with advanced (stage III unresectable or stage IV) melanoma treated on phase III clinical trials has risen from 25-30%
(1) to over 70%, and has resulted in the approval of at least eight drug therapies by the USA Food and Drug Administration (FDA) and in other countries around the world. This revolution is due to two independent developments in drug therapy: first, the targeted inhibition of the mitogen activated protein kinase pathway in V600 BRAF mutant melanoma; and second, the manipulation of the host immune response to tumour via inhibitors of immune checkpoints on T cells, namely the cytotoxic T lymphocyte associated protein 4 (CTLA-4) receptor and the programmed death 1 (PD-1) receptor. Now, the first combination of immune checkpoint inhibitors has had accelerated FDA approval for the treatment of BRAF wildtype advanced melanoma. This drug update reviews the preclinical and clinical studies underpinning the approval of ipilimumab, an inhibitor of CTLA-4, combined with nivolumab, an inhibitor of PD-1.
CTLA-4 Inhibition; Ipilimumab
Following activation by antigen presentation cells in peripheral lymphoid organs, T cells upregulate CTLA-4 expression. CTLA-4 is a co-inhibitory molecule which binds B7 with higher affinity than the co-stimulatory molecule CD28, and the displacement of CD28 for CTLA-4 causes the suppression of T cell activity (2) . Further, CTLA-4 also reduces TCR activation induced tyrosine phosphorylation via the recruitment of the SHP-1/2 phosphatases (3). Ipilimumab has been shown to improve survival in two phase III studies in advanced melanoma. In the second line trial, ipilimumab alone (3mg/kg) or in combination with the glycoprotein 100 vaccine (gp100) improved the OS compared with gp100 alone (median OS gp100 alone 6.4 months vs. ipilimumab alone 10.1 months [Hazard Ratio (HR) 0.68, P<0.001] or vs. ipilimumab+gp100 10 months [HR, vs gp100 alone, 0.66, P=0.003]) (4) . In the first line trial, dacarbazine combined with a higher dose of ipilimumab (10mg/kg) improved the OS compared with dacarbazine alone (11.2 months vs. 9.1 months, HR 0.72; P<0.001) (5) .
Despite marginal improvements in the median OS, the benefit of ipilimumab is due to the long-term duration of disease control with approximately 20% of patients surviving beyond 5 years (6). In both trials, the RECIST response rate for the ipilimumab containing arms was approximately 10%, with clinical benefit and prolonged survival seen in patients who do not undergo conventional radiological responses. Furthermore, a subset of patients may progress before they respond. This phenomenon, termed 'pseudo-progression', led to the development of the immune response criteria (iRC) and the need to confirm progression, in addition to traditional confirmation of response (7).
PD-1 Inhibition; Nivolumab
PD-1 is an inhibitory receptor expressed on cytotoxic T cells, and is a hallmark of T cell exhaustion and dysregulation. One of its ligands, PD-L1, is expressed by tumour cells in response to IFN produced by activated T cells (8) . PD-L1 expression may also be induced by other mechanisms, for example oncogenic signalling pathways (e.g. MYC overexpression (9)), and is an area of intense research. Nivolumab is an IgG4 monoclonal antibody that inhibits PD-1 resulting in activation of the T cell response against tumour cells (Figure 1 ). physician's choice chemotherapy in patients who had progressed on ipilimumab (10) .
Finally, in a first-line phase III study (discussed below), nivolumab had a higher response rate and prolonged PFS compared with ipilimumab irrespective of BRAF mutation status (11).
Pembrolizumab is another anti-PD-1 antibody approved in many countries around the world for the treatment of advanced melanoma. It has also demonstrated a superior response rate, PFS and OS compared with ipilimumab in a phase III clinical trial, with a similar toxicity profile to nivolumab (12) .
Combined CTLA4 and PD-1 inhibition; Ipilimumab combined with Nivolumab

Rationale
The primary site of action of ipilimumab is during the induction phase of anti-tumor T cell immunity within lymphoid tissues, whereas nivolumab primarily acts at the effector phase within the tumour microenvironment (Figure 1 ), suggesting their effects may be additive or synergistic. In preclinical models, mice deficient in CTLA-4 develop a rapidly progressive lymphoproliferative disease which is fatal within months (13) . In contrast, PD-1 deficient mice develop autoimmune disease including lupus-like arthritis and glomerulonephritis (14) or antibody-mediated cardiomyopathy (15) . The differing toxicity profiles suggest that the impact of CTLA-4 and PD-1 on T cell activation and function are non-redundant. increased (16) . In the same model the combination of CTLA-4 and PD-1 blockade significantly increased the cure rate in mice (16) .
Clinical Efficacy
The combination of ipilimumab and nivolumab was explored in a phase I study and was initially presented and published in 2013 (17) . Fifty three patients with advanced melanoma received both drugs concurrently every 3 weeks for 4 doses followed by nivolumab alone for a further 4 doses every 3 weeks, then the combination every 12 weeks for 8 doses. An update reporting the OS, an exploratory endpoint, reported a one-and two-year OS of 79% and 69% in BRAF V600 wildtype patients treated with the combination (19) . Similar differences in efficacy were observed in a smaller cohort of BRAF mutant patients.
Checkmate 067 is a first-line placebo-controlled randomized phase III study comparing three arms of treatment in 915 patients with metastatic melanoma; nivolumab combined with ipilimumab or nivolumab alone versus ipilimumab alone (Table 1) and was too immature for OS analysis. A recent update with a minimum follow-up of 18 months, found the landmark 18 month PFS was 46%, 39% and 14% for the combination, nivolumab and ipilimumab arms, respectively (20) . The median duration of response had not been reached for the combination and was 22.3 and 14.4 months for the nivolumab and ipilimumab arms respectively (20) .
Clinical Efficacy and Subgroups
Checkmate 067 is the only phase 3 randomised trial containing the combination of CTLA-4 and PD-1 inhibition, however it was not powered to compare the combination with nivolumab monotherapy, currently the most pressing question in the treatment paradigm of advanced melanoma. Pre-planned, but underpowered analysis of subgroups may suggest those that stand to benefit from the more toxic combination regimen (see Toxicity below). The difference was even greater when PD-L1 negative tumours were defined by a lower cut off of ≤1%. The PD-L1 data needs to be interpreted with caution given the short follow up, lack of OS data and the fact that the study was not powered to compare the combination to single agent nivolumab. Although Checkmate 067 was not powered to define subgroups that may specifically benefit from PD-1 inhibitor based therapy, specific subgroups of interest include those with the BRAF V600 mutation (because molecularly targeted therapies are an alternative first line strategy), an LDH > x2 upper limit of normal (ULN), and patients over 75 years of age. The data are compelling for all three subgroups, with combination ipilimumab and nivolumab superior to ipilimumab irrespective of age, LDH or mutation status (21) . In patients with an LDH>2X the ULN the response rate to the combination was 38%, 22% to nivolumab, and 0%
for ipilimumab (21) . In the BRAF V600 mutant population the response rate to combination was 67%, which was numerically superior to the 37% and 22% response rates observed with nivolumab or ipilimumab alone, respectively.
Toxicity
Combination ipilimumab and nivolumab is associated with increased immune-related adverse events (irAE) as compared to either agent alone. In the phase I study, treatmentrelated grade 3 or 4 toxicities were seen in 53% of patients (17) . In the Checkmate 067 study, treatment-related adverse events of any grade occurred in 96% of patients on the combination arm as compared to 82% and 86% in the nivolumab and ipilimumab arms, respectively (Table 1) . Grade 3 or 4 treatment-related adverse events were also more common with the combination; 55% compared with 16% and 27% for nivolumab and ipilimumab, respectively. The most common grade 3 and 4 irAEs in the combination arm of CheckMate-067 study were diarrhoea (9.3%), increased transaminases (ALT 8.3%, AST 6.1%) and colitis (7.7%). Toxicities affecting more than one organ system occurred more commonly with the combination; 25% of patients had grade 2 or greater toxicities affecting 
more than one organ (e.g. a patient with both GI toxicity and skin toxicity), and 7% of patients had 3 or more organ systems affected (21) .
The toxicities seen with the combination were similar to those seen with either single agent, however were more frequent and of higher grade, but were manageable with standard algorithms. In Checkmate 067 toxicities led to treatment discontinuation in 36% of patients treated with the combination, 8% of patients treated with nivolumab and 15% of patients treated with ipilimumab (11) . Of interest the response rates were not reduced in patients who discontinued due to toxicity, with responses seen in 68% (81/120), 85% (23/27), and 30% (14/47) of patients who discontinued treatment with the combination, nivolumab or ipilimumab respectively, responses were ongoing in approximately in 70% of patients who discontinued across all three treatment arms (21) . Excluding endocrinopathies, most toxicities resolved with standard treatment algorithms, immunomodulatory agents other than steroids (e.g. infliximab) were used in 6.1%, 0.6% and 5.1% of patients treated with the combination, nivolumab or ipilimumab (11) . There were no treatment-related deaths in the combination arm of Checkmate 067, however the 3 deaths (4%) in the combination arm of Checkmate 069 were potentially due to treatment (18) . In an analysis of toxicity by subgroups in Checkmate 067, increased toxicity was not noted in any particular patient subgroup, including those aged >75 years (21) . The generalisability of these results beyond a clinical trial patient population remains to be determined. The phase I study of ipilimumab combined with nivolumab included a sequential cohort of patients who had received at least 3 doses of ipilimumab (last dose between 4 to 12 weeks prior to enrolment) and were treated with the standard dose nivolumab (3mg/kg) every 2 weeks. Patients with a CR or symptomatic progression after ipilimumab were excluded (17) .
Responses were seen in 6 of 30 (20%) of patients, and 18% of patients experienced a grade 3 or 4 treatment related adverse event (17) . Sequencing of ipilimumab and nivolumab was further explored in a randomized phase II study, Checkmate 064. Patients were treated with either 12 weeks of nivolumab (cohort A) or ipilimumab (cohort B) at standard doses followed by a switch for a further 12 weeks of treatment. All patients were subsequently treated with nivolumab until progression or unacceptable toxicity (22) . The rate of grade 3 or 4 treatment related adverse events at the end of 24 weeks were similar between the 2 groups, 50% and 43% for cohort A and B, respectively. The response rate at 25 weeks appeared numerically higher in cohort A (48%) as compared to cohort B which received ipilimumab first (23%). Caution is required in interpreting the results of this study given it was underpowered (70 patients each arm) and there were differences in baseline characteristics e.g. 42% of patients in the cohort A had PD-L1 positive tumors whereas only 23% were positive in cohort B. Furthermore, the time gap when switching from nivolumab to ipilimumab was 2 weeks, yet it was 3 weeks in the ipilimumab-first arm. Given the halflives of these two drugs, the different time gap would result in a greater overlap of the two drugs in cohort A compared with cohort B.
Given the activity of the combination of ipilimumab and nivolumab in melanoma, it has now been explored in phase I/II studies in other malignancies, including renal cell carcinoma (23) and non-small cell lung cancer (24) . In melanoma, two alternative dosing strategies are being compared in a randomized study; nivolumab 1mg/kg plus ipilimumab 3mg/kg versus nivolumab 3mg/kg plus ipilimumab 1mg/kg (every 3 weeks for 4 doses in both arms) followed by a nivolumab monotherapy (Checkmate-511, NCT02714218).
Combination ipilimumab and pembrolizumab has also been explored in melanoma and renal cell carcinoma. In a phase I study, low dose ipilimumab (1mg/kg) was combined with standard dose pembrolizumab (2mg/kg) and administered every 3 weeks for 4 doses.
Pembrolizumab was continued every 3 weeks for a total of 24 months, disease progression or unacceptable toxicity (25) . In the phase Ib expansion cohort of 153 metastatic melanoma patients, treatment-related AEs occurred in 95% of patients, grade 3-4 treatment-related AEs occurred in 42% (grade3/4 immune related AEs in 25%), and responses were observed in 57% of patients (26) . Without a head to head comparison with the ipilimumab/nivolumab combination it will be difficult to determine if a lower dose of ipilimumab in combination with a higher dose of PD-1 inhibitor maintains efficacy with less toxicity. A third combination of a CTLA-4 inhibitor tremelimumab, and a PD-L1 inhibitor durvalumab showed promising activity in initial analysis of a phase 1 study in patients with NSCLC (27) . 
Patient Selection and Alternative Approaches to Combination Immunotherapy
Given the favourable toxicity profile of single agent PD-1 inhibition and the lack of OS data for the combination of nivolumab and ipilimumab, the use of PD-L1 status as a biomarker for selection of patients to forego combined CTLA-4 and PD-1 blockade appears attractive.
Although biomarkers are usually employed to select for a treatment (e.g. HER2, estrogen, progesterone in breast cancer, BRAF mutations in melanoma), not to forgo it, there may be an argument to spare a proportion of patients from the increased risk of toxicity of the combination. This is being examined in Checkmate 067, and may assist in some clinical decisions, however it is important to emphasise that the study is not sufficiently powered to (29) and a high level of neo-antigens, which in turn are associated with a high mutational burden in the tumour (30) . It remains to be determined if such markers will be useful in selecting patients for single agent anti-PD1 therapy versus the combination.
Furthermore, early during treatment biopsies may be more predictive of tumour response to anti-PD1 therapy and define subsets of patients who require a different treatment strategy (31).
The financial cost, both of the drugs and the ensuing toxicities, may impact the use of the combination around the world. A systematic examination is yet to be reported, but a rational cost benefit analysis compared with single agent is likely to require maturation of the survival data from CheckMate 067 (32) . In some health systems, the combination may be cost prohibitive, however biomarker driven patient selection algorithms may minimise the financial impact.
In an effort to improve the efficacy of PD-1 inhibition, without significant increases in toxicity, multiple combinations of therapies with an anti-PD1 backbone are in clinical development or in planning, and have been reviewed elsewhere (33) . Three randomized clinical trials in advanced melanoma of such combination therapies compared with anti-PD1 monotherapy warrant further discussion. overall response rate of 57% (unconfirmed response rate 67%) in 21 patients treated in a phase I study (36) . A placebo controlled phase III study comparing TVEC combined with pembrolizumab with pembrolizumab and a matched placebo is currently underway (NCT02263508).
As both TVEC and epacadostat combined with PD-1 blockade are being compared to single agent PD-1 inhibition in phase III studies, it will remain difficult to compare these newer immune combinations with ipilimumab/nivolumab. An alternative approach is the combination of molecularly targeted and immune therapies.
In mouse models the combination of BRAF and/or MEK inhibitors is synergistic with anti-PD-1 therapy (37) . In preliminary data from the phase I study of dabrafenib + trametinib in combination with pembrolizumab unconfirmed responses were seen in 9 of 15 (60%) patients (38) . The phase 2 portion of this study compares dabrafenib + trametinib combined with pembrolizumab versus dabrafenib + trametinib combined with a matched placebo more mature data, the combination cannot yet be considered the standard of care, particularly given the high rates of immune-related toxicities compared with PD-1 inhibition alone. There may be subgroups of patients who particularly benefit from the combination (for example, patients with rapidly progressing BRAF wildtype melanoma or patients with a high baseline LDH), and validation of biomarkers, such as PD-L1 along with studies in specific patient subtypes are required to assist in patient selection. Multiple alternative immunotherapy combinations are currently in clinical development with the hope that correlative science will allow treatments to be individualised to further improve patient outcomes, with less toxicity. 
